Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction

被引:48
作者
Vanderheyden, M.
Bartunek
Claeys, G.
Manoharan, G.
Beckers, J. F.
Ide, L.
机构
[1] Onze Lieve Vrouw Hosp, Ctr Cardiovasc, B-9400 Aalst, Belgium
[2] Univ Ziekenhuis Gasthuisberg, Lab Med Clin Chem, B-3000 Louvain, Belgium
[3] Onze Lieve Vrouw Hosp, Biochem Lab, B-9400 Aalst, Belgium
关键词
B-type natriuretic peptides; heart failure; cardiac markers;
D O I
10.1016/j.clinbiochem.2006.01.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Human pro-B-type natriuretic peptide is cleaved into the active B-type natriuretic peptide (BNP) and the inactive fragment NT-proBNP. It is unclear if, similar to BNP, NT-proBNP can be used as a marker of impaired left ventricular (LV) ejection fraction (EF). This study evaluated the analytical performance of both assays to detect LV systolic dysfunction. Methods: In 72 patients with various degrees of left ventricular systolic dysfunction (LVSD), blood analysis for BNP and NT-proBNP was performed prior to cardiac catheterization, using a point-of-care analyzer (Biosite) and a fully automated laboratory analyzer (Roche-Elecsys), respectively. The within-run and between-run imprecision for BNP and NT-proBNP was calculated. Results: Both markers were able to detect impaired LV EF with the largest area under the receiver-operating-characteristic curve for NT-proBNP (NT-proBNP: 0.851 (0.747-0.924); BNP: 0.803 (0.692-0.887) 95% confidence interval; P = 0.07). A significant correlation was observed between BNP and NT-proBNP (r 0.9; P < 0.0001). Estimating the within-run imprecision, the coefficient of variance for BNP was 3.14% (n = 20, mean 316 ng/L) to 3.32% (n 20, mean 820 ng/L) and for NT-proBNP 0.9% (n = 20, mean 4390.8 ng/L) to 1.4% (n = 20, mean 225 ng/L). The between-run imprecision for NT-proBNP ranged between 2.1% (n = 20, mean 224.6 ng/L) and 2% (n = 20, mean 4391 ng/L). Optimal discriminator values for BNP and NT-proBNP were 139 ng/L and 358 ng/L, respectively. However, adjusting the BNP cut-off value to 54 ng/L improved the negative predictive value and sensitivity of the assay. Conclusion: Similar to BNP, NT-proBNP is a promising marker in identifying LVSD. Although both assays are reliable and have good analytical performance, their diagnostic cut-off value is dynamic and population-dependent. The slightly wider detection range and the more stable structure of NT-proBNP compared to the BNP assay suggest that NT-proBNP could play an additional role in the evaluation of patients with LV systolic dysfunction. (c) 2006 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:640 / 645
页数:6
相关论文
共 23 条
[21]   Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure [J].
Wu, AHB ;
Smith, A ;
Wieczorek, S ;
Mather, JF ;
Duncan, B ;
White, CM ;
McGill, C ;
Katten, D ;
Heller, G .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (05) :628-631
[22]   LOCALIZATION AND MECHANISM OF SECRETION OF B-TYPE NATRIURETIC PEPTIDE IN COMPARISON WITH THOSE OF A-TYPE NATRIURETIC PEPTIDE IN NORMAL SUBJECTS AND PATIENTS WITH HEART-FAILURE [J].
YASUE, H ;
YOSHIMURA, M ;
SUMIDA, H ;
KIKUTA, K ;
KUGIYAMA, K ;
JOUGASAKI, M ;
OGAWA, H ;
OKUMURA, K ;
MUKOYAMA, M ;
NAKAO, K .
CIRCULATION, 1994, 90 (01) :195-203
[23]   Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay [J].
Yeo, KTJ ;
Wu, AHB ;
Apple, FS ;
Kroll, MH ;
Christenson, RH ;
Lewandrowski, KB ;
Sedor, FA ;
Butch, AW .
CLINICA CHIMICA ACTA, 2003, 338 (1-2) :107-115